Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations

Fig. 7

Anti-tumor efficacy of D2C7-IT and immune checkpoint inhibitor combinations in orthotopic glioma models. a and c Survival curves and median survival estimates data are shown for C57BL/6 J mice bearing intracranial CT-2A-dmEGFRvIII-Luc tumors (a) and VM/Dk mice bearing intracranial SMA560-dmEGFRvIII-Luc tumors (c) treated with vehicle control, D2C7-IT monotherapy, or D2C7-IT+αPD-1/αPD-L1/αTim-3/αLag-3/αCD73 combinations. The p-values generated from the generalized Wilcoxon test are provided for both tumor models and are not adjusted for multiple testing. b and d Median survival for mice that survived to Day 77, and were re-challenged in the contralateral hemisphere of the brain with 2 × 105 CT-2A (b), or 3 × 104 SMA560 (d) parental cells. C57BL/6 J mice (N = 5) or VM/Dk (N = 5) were used as naïve controls

Back to article page